Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta Inc (Nasdaq: AZTA) is a global leader in life sciences solutions, providing essential tools for drug development, clinical research, and genomic discovery. This page aggregates official press releases and verified news about the company’s advancements in cold-chain sample management, automated storage systems, and multiomics services.
Investors and researchers will find timely updates on Azenta’s operational milestones, including earnings reports, strategic partnerships, product innovations, and industry recognition. The curated content addresses key areas such as sample integrity technologies, genomic data accuracy, and global service expansions.
Key updates include developments from Azenta’s core segments: Life Sciences Products (automated storage solutions, lab consumables) and Life Sciences Services (genomic sequencing, multiomics analytics). Content is organized to help stakeholders track progress in critical research areas like precision medicine and biotherapeutic development.
Bookmark this page for streamlined access to Azenta’s latest announcements, or check regularly for insights into how the company continues to shape the future of life sciences infrastructure and biomedical innovation.
Azenta, Inc. (Nasdaq: AZTA) will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15-16, 2023. Interested participants should contact their BTIG representative to attend. Azenta is recognized globally for providing life sciences solutions, facilitating faster market delivery of breakthroughs and therapies. Their comprehensive offerings include cold-chain sample management and genomic services, primarily serving pharmaceutical, biotech, academic, and healthcare institutions worldwide. The company is based in Burlington, MA, with operations spanning North America, Europe, and Asia.
Azenta, Inc. (Nasdaq: AZTA) reported Q1 2023 revenue of $178 million, a 28% year-over-year increase, driven by an 80% surge in Life Sciences Products revenue, thanks to the acquisition of B Medical. Organic revenue growth, excluding COVID impacts, stood at 7%.
Despite these gains, the company recorded a diluted EPS loss of ($0.15) and an operating loss of $28 million. Management aims to streamline operations for a projected 2% margin improvement in the second half of FY23. Guidance for Q2 2023 estimates revenue between $156 million and $171 million with a non-GAAP EPS forecast of (0.04) to 0.04.
Azenta, Inc. (Nasdaq: AZTA) is set to announce its fiscal first quarter 2023 earnings on February 8, 2023, after market close. The earnings period concluded on December 31, 2022. Following the announcement, the company will hold a conference call at 4:30 p.m. ET to discuss the financial results. Analysts and investors can dial in or access the live webcast via the Azenta website. Azenta, headquartered in Burlington, MA, provides life sciences solutions, including cold-chain sample management and genomic services, aiding pharmaceutical, biotech, and healthcare sectors globally.
Azenta, Inc. (NASDAQ: AZTA) has announced the acquisition of Ziath, Ltd., a leading provider of 2D barcode readers based in Cambridge, UK, enhancing Azenta's life sciences workflow solutions. This strategic acquisition is expected to improve offerings across the sample lifecycle, aligning with Azenta's current products. CEO Neil Benn will continue leading Ziath under Azenta’s umbrella. The transaction is anticipated to be accretive to non-GAAP earnings for FY 2023 and GAAP earnings for FY 2024, showcasing a promising financial outlook.
Azenta, Inc. (Nasdaq: AZTA) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, in San Francisco, CA. The management presentation is scheduled for 3:45 pm PST, and a live webcast will be accessible via the Azenta investor relations website. A replay will be available after the event. Azenta specializes in life sciences solutions, offering cold-chain sample management and genomic services to support drug development and clinical research globally.
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the 25th Annual Needham Growth Conference on January 11, 2023, in New York, NY. The presentation will begin at 11:00 am ET and can be accessed via a live webcast on Azenta's investor relations website. Following the event, a replay will be available. Azenta is known for providing life sciences solutions, including cold-chain sample management and genomic services, aimed at accelerating breakthroughs in drug development and advanced therapies.
Cabot Corporation (NYSE: CBT) announced the promotion of three senior leaders to Executive Vice President: Hobart C. Kalkstein, Erica McLaughlin, and Jeff Zhu. Kalkstein oversees the Reinforcement Materials Segment, McLaughlin serves as CFO and Head of Corporate Strategy, and Zhu directs the Performance Chemicals Segment. CEO Sean Keohane praised their significant contributions and expressed excitement about their expanded roles in driving the company's growth strategy. This leadership enhancement is seen as a strategic move to bolster Cabot's performance and sustainability initiatives.
Azenta, Inc. (Nasdaq: AZTA) announced a $500 million accelerated share repurchase (ASR) agreement with JP Morgan Chase Bank to enhance shareholder value. This ASR is part of a larger $1.5 billion share repurchase authorization, with an additional $500 million planned for repurchases over the next year. The initial delivery will be approximately 6.1 million shares on November 28, 2022, and the final settlement is expected by June 30, 2023. The ASR aims to optimize capital allocation and boost earnings per share (EPS).
Azenta, Inc. (Nasdaq: AZTA) reported expected Q4'22 revenue of $138 million, marking no change year-over-year, with a 30% growth forecast for fiscal 2023. Excluding COVID impacts, organic growth reached 12% in Q4 and 17% for the year. The Board of Directors authorized a $1.5 billion share repurchase program, intending to buy back at least $1 billion of common stock. Despite a diluted EPS of ($0.07), management noted strong performance in life sciences services and a focus on growth alongside an acquisition of B Medical Systems.
Azenta, Inc. (Nasdaq: AZTA) has nominated Tina S. Nova, Ph.D., and Dorothy E. Puhy for election to its Board of Directors during the 2023 Annual General Meeting. Both nominees will join the Board as non-voting observers immediately. Nova brings over 25 years of experience in life sciences, previously leading companies that engaged in significant acquisitions, including Decipher Biosciences. Puhy, with extensive expertise from her tenure at Dana-Farber Cancer Institute, has held key leadership roles. This Board refreshment aims to enhance Azenta's strategic direction and support its transformation efforts.
